BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
293.27
-11.35 (-3.73%)
At close: May 15, 2026, 4:00 PM EDT
298.00
+4.73 (1.61%)
After-hours: May 15, 2026, 7:46 PM EDT
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 11 analysts that cover BeOne Medicines AG stock have a consensus rating of "Buy" and an average price target of $387.82, which forecasts a 32.24% increase in the stock price over the next year. The lowest target is $290 and the highest is $425.
Price Target: $387.82 (+32.24%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 8 | 8 | 8 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $423 → $425 | Buy | Maintains | $423 → $425 | +44.92% | May 7, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $410 → $420 | Strong Buy | Maintains | $410 → $420 | +43.21% | May 7, 2026 |
| Barclays | Barclays | Buy Maintains $405 → $409 | Buy | Maintains | $405 → $409 | +39.46% | May 7, 2026 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $411 → $413 | Strong Buy | Reiterates | $411 → $413 | +40.83% | May 7, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $400 | Buy | Initiates | $400 | +36.39% | May 4, 2026 |
Financial Forecast
Revenue This Year
44.01B
from 5.34B
Increased by 723.76%
Revenue Next Year
50.63B
from 44.01B
Increased by 15.04%
EPS This Year
38.65
from 2.47
Increased by 1,464.71%
EPS Next Year
65.08
from 38.65
Increased by 68.40%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 48.7B | 57.2B | ||||||
| Avg | 44.0B | 50.6B | ||||||
| Low | 41.0B | 45.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 811.1% | 29.9% | ||||||
| Avg | 723.8% | 15.0% | ||||||
| Low | 666.9% | 3.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 48.17 | 94.38 | ||||||
| Avg | 38.65 | 65.08 | ||||||
| Low | 26.54 | 34.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1,850.2% | 144.2% | ||||||
| Avg | 1,464.7% | 68.4% | ||||||
| Low | 974.6% | -11.9% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.